RGTLF (Argent Biopharma) Tariff Resilience Score: 7/10 (As of Jun. 27, 2026)


What is Argent Biopharma Tariff Resilience Score?

Argent Biopharma RGTLF Tariff Resilience Score is 7 as of Jun. 27, 2026. The stock has 8 warning signs investors should review. Among 1,031 Drug Manufacturers companies, Argent Biopharma ranks better than 97.09% on this metric.

Argent Biopharma has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Argent Biopharma has Argent Biopharma's exposure to tariffs is moderate, as the pharmaceutical industry often benefits from exemptions. The company has a global supply chain but can leverage alternative suppliers. Historical impacts have been minimal, and the company has some pricing power in its niche markets.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Argent Biopharma might have Highly Resilient.

Argent Biopharma  (OTCPK:RGTLF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Argent Biopharma Tariff Resilience Score Related Terms

RGTLF vs ZTS, UTHR: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Argent Biopharma's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Argent Biopharma Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Argent Biopharma's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Argent Biopharma's Tariff Resilience Score falls into.


What does a Tariff Resilience Score of 7 mean?
Argent Biopharma (RGTLF) has a Tariff Resilience Score of 7 as of Jun. 27, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Argent Biopharma ranks #30 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Argent Biopharma's Tariff Resilience Score too high?
Argent Biopharma's current Tariff Resilience Score is 7. Based on the distribution chart, Argent Biopharma ranks #30 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Argent Biopharma's Tariff Resilience Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Argent Biopharma ranks #30 out of 1031 companies for Tariff Resilience Score. This places Argent Biopharma in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Argent Biopharma's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argent Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Argent Biopharma (RGTLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 25% above its estimated fair value. The current Tariff Resilience Score is 7. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Argent Biopharma (RGTLF), the current Tariff Resilience Score is 7 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Argent Biopharma Business Description

Other Exchanges H5O0:GermanyRGT:Australia
Address 295 Rokeby Road, Suite 1, Subiaco, WA, AUS, 6008
Argent Biopharma Ltd is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others. Its geographic areas are Malta, Slovenia and others, and Australia. The group generates the majority of its revenue from Slovenia and others.